This has been demonstrated by Zhe Liu et al [18], who showed that a complex of aptamer and doxorubicin could selectively deliver doxorubicin to HER2-positive breast cancer cells, with minimal binding to HER2-negative cells. Here, ERBB2 is linked to breast carcinoma.